Company Overview

Myomo, Inc. is a U.S.-based medical robotics and wearable medical technology company focused on developing powered orthotic devices intended to improve arm and hand function for individuals with neurological disorders and upper-limb paralysis. The company operates within the medical device, rehabilitation technology, and neuro-robotics industries. Its primary product line is the MyoPro orthosis, a wearable powered brace designed to detect weak electromyography (EMG) signals from a patient’s muscles and assist movement of the elbow, wrist, and hand. Revenue is primarily generated through sales and reimbursement-supported distribution of these devices to patients, healthcare providers, and rehabilitation networks.

The company serves individuals affected by stroke, brachial plexus injury, spinal cord injury, multiple sclerosis, and other neuromuscular conditions. Myomo’s strategic positioning is centered on proprietary myoelectric control technology that enables users with limited muscular activity to regain functional movement. Originally developed from research conducted at the Massachusetts Institute of Technology (MIT), the company commercialized its technology during the mid-2000s and later became publicly traded through a reverse merger transaction. Public disclosures in SEC filings and investor materials indicate that Myomo has increasingly focused on direct billing, reimbursement support, and patient acquisition infrastructure to expand adoption of the MyoPro platform.

Business Operations

Myomo operates primarily through a single reporting segment focused on the commercialization of powered upper-limb orthoses. The company designs, manufactures, markets, and distributes the MyoPro product family, including customized orthotic solutions fitted to individual patients. Revenue generation depends largely on insurance reimbursement approvals, direct patient referrals, Veterans Affairs relationships, rehabilitation clinic engagement, and orthotist partnerships. The company’s operational model includes patient evaluation, clinical fitting, fabrication coordination, and ongoing support services.

Operations are concentrated in the United States, though the company has historically pursued select international activities through distributors and strategic relationships. Myomo controls proprietary EMG-based motion detection and assistive movement technologies embedded within the MyoPro device platform. The company has collaborated with rehabilitation centers, orthotics providers, and veterans’ healthcare systems to support distribution and clinical adoption. Public disclosures identify a reliance on specialized manufacturing, regulatory compliance, reimbursement management, and intellectual property protection as central operational components.

Strategic Position & Investments

Myomo’s strategic direction has focused on expanding reimbursement coverage, increasing patient awareness, improving clinical outcomes, and scaling commercial operations. The company has invested in marketing infrastructure, patient outreach systems, and clinical support capabilities intended to increase prescription volume and insurance approval rates. Management has also emphasized improvements in manufacturing efficiency and device customization to support broader adoption of the MyoPro platform.

The company’s growth initiatives include expanding relationships with rehabilitation hospitals, neurologists, orthotists, and veterans’ healthcare providers. Myomo has also pursued technology enhancements related to lighter device construction, software integration, and improved user functionality. Publicly available filings and investor presentations indicate that the company continues to position itself within the broader wearable robotics and assistive healthcare technology sectors rather than diversifying into unrelated medical device categories. Data regarding material acquisitions or large-scale subsidiary investments remains limited in public disclosures, and no major transformative acquisition activity has been consistently verified through available public sources.

Geographic Footprint

Myomo is headquartered in Burlington, Massachusetts, and derives the substantial majority of its revenue from the United States market. The company’s principal commercial activities, reimbursement efforts, and patient support infrastructure are concentrated domestically, particularly through relationships with U.S. healthcare providers, orthotics clinics, and insurers. The company has also engaged with the U.S. Department of Veterans Affairs and related rehabilitation systems as part of its domestic outreach strategy.

Internationally, Myomo has maintained a more limited presence through distributor arrangements and selective market development activities in regions including Europe and parts of Asia. Public filings indicate that international revenue has historically represented a smaller portion of overall operations relative to the U.S. market. The company’s operational influence outside North America appears focused primarily on technology licensing, distributor partnerships, and exploratory commercialization efforts rather than large-scale manufacturing or foreign subsidiary expansion.

Leadership & Governance

Myomo’s leadership team combines experience in medical devices, healthcare commercialization, rehabilitation technology, and public company management. The company originated from technology research associated with MIT and has evolved into a commercially focused medical technology enterprise emphasizing reimbursement-driven growth and clinical adoption. Management communications in investor materials and SEC filings consistently emphasize improving patient mobility outcomes, expanding insurance access, and achieving operational scalability.

Key executives and leadership figures include:

• Paul R. Gudonis – Chairman and Chief Executive Officer
• David Henry – Chief Financial Officer
• Micah Mitchell – Chief Commercial Officer
• Kevin Kliman – Vice President of Engineering and Product Development
• Thomas F. Kirk – Lead Independent Director

The company’s governance structure includes a board of directors with backgrounds in healthcare, finance, medical technology, and commercialization. Leadership strategy has emphasized disciplined commercial expansion, reimbursement execution, and continued development of proprietary assistive robotics technology.